Wall Street Zen Upgrades Clorox (NYSE:CLX) to Hold

Clorox (NYSE:CLX) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

CLX has been the topic of a number of other research reports. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Clorox from $114.00 to $112.00 and set a “hold” rating on the stock in a report on Wednesday, February 4th. TD Cowen boosted their target price on Clorox from $108.00 to $111.00 and gave the company a “hold” rating in a research note on Wednesday, February 4th. BNP Paribas Exane dropped their price target on Clorox from $103.00 to $101.00 and set an “underperform” rating on the stock in a research report on Friday, January 16th. Royal Bank Of Canada set a $132.00 price target on Clorox in a research note on Wednesday. Finally, Evercore lowered their price objective on Clorox from $132.00 to $115.00 and set an “underperform” rating on the stock in a research note on Wednesday, February 4th. One investment analyst has rated the stock with a Buy rating, ten have issued a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $117.93.

Clorox Trading Up 1.6%

NYSE CLX opened at $119.52 on Friday. The business’s fifty day moving average is $105.83 and its 200-day moving average is $113.73. The company has a debt-to-equity ratio of 71.03, a current ratio of 0.74 and a quick ratio of 0.48. The stock has a market capitalization of $14.45 billion, a price-to-earnings ratio of 19.53, a PEG ratio of 0.59 and a beta of 0.59. Clorox has a one year low of $96.66 and a one year high of $159.04.

Clorox (NYSE:CLX) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.39 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.04). The company had revenue of $1.67 billion for the quarter, compared to analysts’ expectations of $1.64 billion. Clorox had a return on equity of 383.01% and a net margin of 11.17%.The business’s quarterly revenue was down .8% on a year-over-year basis. During the same quarter last year, the business posted $1.55 EPS. Equities research analysts predict that Clorox will post 7.15 EPS for the current year.

Insider Buying and Selling at Clorox

In other news, Director Pierre R. Breber purchased 4,000 shares of the stock in a transaction dated Friday, November 21st. The shares were purchased at an average cost of $104.13 per share, with a total value of $416,520.00. Following the completion of the acquisition, the director owned 13,000 shares in the company, valued at $1,353,690. This represents a 44.44% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.63% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Clorox

Several hedge funds have recently bought and sold shares of the company. Invesco Ltd. boosted its holdings in Clorox by 138.3% in the 2nd quarter. Invesco Ltd. now owns 3,245,175 shares of the company’s stock valued at $389,648,000 after purchasing an additional 1,883,465 shares during the period. Norges Bank bought a new stake in Clorox during the second quarter valued at $190,429,000. Van ECK Associates Corp boosted its stake in Clorox by 93.9% during the third quarter. Van ECK Associates Corp now owns 2,709,972 shares of the company’s stock valued at $334,139,000 after buying an additional 1,312,471 shares during the period. Arrowstreet Capital Limited Partnership grew its position in Clorox by 218.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,249,127 shares of the company’s stock worth $149,983,000 after buying an additional 856,873 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its stake in Clorox by 6,907.9% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 749,703 shares of the company’s stock worth $75,593,000 after acquiring an additional 739,005 shares during the last quarter. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Key Headlines Impacting Clorox

Here are the key news stories impacting Clorox this week:

• Positive Sentiment: Morgan Stanley raised its price target on CLX to $136 (maintained equal-weight), citing valuation/earnings dynamics — a catalyst supporting the stock’s rally. Clorox (NYSE:CLX) Price Target Raised to $136.00 at Morgan Stanley
• Positive Sentiment: Investor write-ups are bullish: a Seeking Alpha piece frames CLX as a defensive, dividend-rich value after “solid” Q2 results and attractive valuation — supporting buy interest from income-focused investors. Clorox: Solid Q2 Results And Cheap Valuation MakesThis Defensive Dividend Stock A Strong Buy
• Neutral Sentiment: TD Cowen nudged its price target to $111 and kept a Hold rating — a modest recalibration that tempers upside expectations despite the recent positive headlines. TD Cowen Adjusts Clorox Price Target
• Neutral Sentiment: Company reported mixed Q2 results and reaffirmed its 2026 outlook — revenue roughly flat year-over-year and an EPS miss by a few cents; reassurances on the outlook limit downside but leave questions on near-term margin recovery. Clorox Posts Mixed Q2 Results, Reaffirms 2026 Outlook
• Neutral Sentiment: Management is weighing a potential GOJO acquisition and finishing an ERP implementation; strategic moves could boost long-term growth but add execution risk in the near term. Clorox Weighs GOJO Deal And ERP Finish Against Softer Earnings
• Neutral Sentiment: Q2 earnings call transcript is available for deeper read on management commentary around pricing, cost savings and margin plans — useful for gauging execution risk. Clorox (CLX) Q2 2026 Earnings Call Transcript
• Negative Sentiment: Some brokerages have a consensus “Reduce” rating on CLX, which may cap upside as institutional flows react to conservative guidance and margin concerns. The Clorox Company Given Consensus Rating of “Reduce” by Brokerages
• Negative Sentiment: BofA flagged margin uncertainty after the Q2 EPS miss — a reminder that cost and margin recovery, not just revenue, will drive forecast revisions and investor sentiment. BofA Flags Margin Uncertainty for Clorox After Q2 Earnings Miss
• Neutral Sentiment: A Zacks piece highlights using its Earnings ESP tool to find staples stocks that might beat — general market research, not CLX-specific guidance, but could affect short-term trading interest. Why Investors Need to Take Advantage of These 2 Consumer Staples Stocks Now

About Clorox

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.